Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.
about
The CD200-CD200 receptor inhibitory axis controls arteriogenesis and local T lymphocyte influx.Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesisIL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytomaIL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy.A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.Expression of CD200 on AML blasts directly suppresses memory T-cell function.Myogenic properties of human mesenchymal stem cells derived from three different sources.Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.
P2860
Q33712157-EFE24E93-E717-46DA-90EE-4199BA226A01Q34154823-D9B19FB6-CCE7-468A-A3A0-8D530825A86EQ34353081-76BBDEEF-B7D1-452D-900B-B4AE6158F7C7Q34647584-D37C81F9-635B-4483-8CFF-9119F34A829FQ35757368-843E7604-D5F5-4829-A3D2-416CC7E9FA18Q35799158-CBEF79EB-B829-4B21-9E29-6EDB6C7FB706Q36763672-87CB93F2-7219-404D-8750-DFFEDD7849ECQ37636535-EAB23A76-F006-43F5-9594-6FD883F91E45Q38036688-A3A894A5-99BC-431B-8541-89F0380C43E7Q41474685-284F4328-B86A-4CDA-9729-08E33204BAF9Q42376556-217BF3AB-DCDA-41AA-ABE9-643BE3D85C9DQ42572899-5230605C-50D1-4068-96B4-6656EFB9A250Q42604796-2697E72D-F400-40E5-8984-1C93C743DB77Q46952293-CE49E016-C368-493E-BA66-C26D279BBBD6Q52892251-893C65C4-3F5E-4E18-A525-AD18DA28F920
P2860
Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@ast
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@en
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@nl
type
label
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@ast
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@en
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@nl
prefLabel
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@ast
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@en
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@nl
P2093
P2860
P356
P1476
Tumor expression of CD200 inhi ...... immune evasion of CTL therapy.
@en
P2093
Fatemeh Talebian
Hani Y El-Omrani
Jin-Qing Liu
Lixin Wang
Mazin Khattabi
Xue-Feng Bai
P2860
P304
P356
10.1002/EJI.201040472
P407
P577
2010-09-01T00:00:00Z